Teva Pharm sees close of $40.5 billion Allergan generics deal by June
TEL AVIV (Reuters) - Israel-based Teva Pharmaceutical Industries said on Tuesday it now expects its $40.5 billion acquisition of the generic drug activities of Allergan to be completed by June.
No comments:
Post a Comment